Compounds > 1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole
Page last updated: 2024-09-03

1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole and 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide

1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole has been researched along with 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide in 1 studies

Compound Research Comparison

Studies
(1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole)		Trials
(1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole)		Recent Studies (post-2010)
(1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole)		Studies
(5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide)		Trials
(5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide)		Recent Studies (post-2010) (5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide)
17022105

Protein Interaction Comparison

ProteinTaxonomy1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole (IC50)5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (IC50)
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.0285
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.005
Integrase Human immunodeficiency virus 10.5167

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Clercq, E; Liu, X; Pannecouque, C; Zhan, P1

Reviews

1 review(s) available for 1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole and 5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide

ArticleYear
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
    Journal of medicinal chemistry, 2016, Apr-14, Volume: 59, Issue:7

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Chemoprevention; Drug Design; Drug Discovery; Drug Resistance, Viral; HIV Protease Inhibitors; Humans; Molecular Targeted Therapy; Mutation; Prodrugs; Solubility; Structure-Activity Relationship

2016